AstraZeneca and Silence Therapeutics have entered into a collaboration focused on the development of new approaches for the delivery of siRNA molecules. Silence has expertise in the delivery of siRNA molecules, in particular with the functional systemic delivery of siRNA in vivo using its AtuPLEX technology. Under the terms of the agreement, the two companies will be allowed to commercialize delivery systems developed under the collaboration. Financial details of the agreement were not disclosed...